首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Therapeutic Advances In Neurological Disorders

Therapeutic Advances In Neurological Disorders杂志,由SAGE Publications Inc.出版,于2008年创刊,Continuous publication,出版语言English,ISSN:1756-2856,E-ISSN:1756-2864。

投稿咨询
Therapeutic Advances In Neurological Disorders
Therapeutic Advances In Neurological Disorders
Therapeutic Advances In Neurological Disorders
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
4
CiteScore
6.1
期刊收录
SCI、SCIE

Therapeutic Advances In Neurological Disorders(中文译名:《神经系统疾病的治疗进展》),ISSN:1756-2856,EISSN:1756-2864,是SAGE Publications Inc.出版的国际性学术期刊,创刊于2008年,以Continuous publication形式稳定发行,2026年总发文量约128篇。该刊采用OA开放访问,学科归属为CLINICAL NEUROLOGY。该刊是医学、临床神经病学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4,2025年期刊CiteScore为6.1,2025年期刊自引率约5%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Therapeutic Advances In Neurological Disorders长期聚焦医学、临床神经病学及相关产业的技术应用前沿,平均审稿周期15 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、临床神经病学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,GERMANY (FED REP GER)USA、Italy、CHINA MAINLAND、Switzerland、England、Spain等为核心发文国家与地区;RUHR UNIVERSITY BOCHUMNATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS、UNIVERSITY OF DUISBURG ESSEN、UNIVERSITY OF LONDON、UNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF BERN、UNIVERSITY OF MUNSTER等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
CLINICAL NEUROLOGY 临床神经病学
3区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
CLINICAL NEUROLOGY 临床神经病学
2区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
CLINICAL NEUROLOGY 临床神经病学
2区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CLINICAL NEUROLOGY SCIE Q1 68 / 296

77.2

学科:CLINICAL NEUROLOGY SCIE Q1 67 / 296

77.53

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:CLINICAL NEUROLOGY SCIE Q1 41 / 277

85.4

学科:CLINICAL NEUROLOGY SCIE Q1 41 / 278

85.43


中国学者近期发文

1
Preliminary observations on the efficacy of efgartigimod in anti-LGI1-associated autoimmune encephaliti

Author:Zuo, Jing-Wen; Dai, Ying-Yue; Liu, Wen-Jing; Zhang, Jia-Ying; Shao, Xiao-Qiu; Wang, Qun; Lv, Rui-Juan

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261437004

2
Brivaracetam monotherapy in juvenile myoclonic epilepsy: a safety and efficacy evaluatio

Author:Zuo, Jing-Wen; Dai, Ying-Yue; Liu, Wen-Jing; Zhang, Jia-Ying; Shao, Xiao-Qiu; Wang, Qun; Lv, Rui-Juan

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261440217

3
Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case serie

Author:Huang, Ying; Xiong, Yihan; Zhan, Hui; Wu, Futian; Jiang, Yichun; Zhang, Yaqing; Chen, Jiaxun; Zeng, Silin; Zhang, Ting; Xiong, Xiaofeng; Chen, Zhuomin; Yang, Fang; Li, Gang; Xu, Qianhui

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261425088

4
Objective tremor monitoring using tri-axis accelerometer in MRgFUS thalamotomy for essential tremor: a feasibility stud

Author:Liu, Kai-Chun; Macerollo, Antonella; Heng, Hoon-Ming; Chen, Pei-Chiang; Lu, Ming-Kuei; Chen, Chun Ming; Tsai, Chon-Haw; Chen, Jui-Cheng

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864251406534

5
Association of atherogenic index of plasma and post-stroke epilepsy in patients with ischemic stroke: a multicenter retrospective study in Chin

Author:Wan, Xichen; Xiong, Ye; Wang, Peng; Wang, Maoqi; Huang, Lianghua; Tang, Yunliang

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261416789

6
Thymectomy with or without maintenance therapy for myasthenia gravis patients: a tri-center, real-world stud

Author:Zhang, Hao; Fan, Moli; Shi, Yutong; Huang, Xiaoyu; Cui, Ying; Yu, Zihao; Yang, Chun-Sheng; Li, Hui-Ning; Zhang, Xiao-He; Liu, Peng; Wu, Ti; Shi, Fu-Dong; Qi, Guo-Yan

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261415757

7
Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safet

Author:Bi, Zhuajin; Ye, Xiaodong; Liu, Peidong; Lu, Mengcao; Liu, Hongbo; Chen, Min

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261419026

8
Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective stud

Author:Zhou, Qian; Ouyang, Yuzhen; Jiang, Fei; Zeng, Qiuming; He, Ting; Wen, Zeyi; Shi, Guanzhong; Dong, Xiaohua; Cai, Haobing; Xiang, Wei; Su, Miao; Li, Kailin; Yang, Huan

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864261421717

9
Comprehensive versus thrombectomy-capable stroke centers: a web-based model to predict outcomes after mechanical thrombectom

Author:Gan, Shujuan; Huang, Weifeng; Yi, Tingyu; Zhang, Wenli; Lu, Xiongwei; Chen, Zhiting; Miao, Jinfeng; Wu, Yanmin; Wu, Meihua; Li, Caixia; Yang, Yining; Ye, Jinhua; Chen, Huanghuang; Wu, Ying; Zhuang, Xiaona; Xu, Yuxin; Jiao, Liqun; Chen, Wenhuo

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864251411020

10
Comorbidity and modifiable risk factors in multiple sclerosi

Author:Zhang, Yao; Dobson, Ruth; Giovannoni, Gavin

Journal: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. 2026; Vol. 19, Issue , pp. -. DOI: 10.1177/17562864251404455


在线咨询

Therapeutic Advances In Neurological Disorders

国际简称:THER ADV NEUROL DISO参考译名:神经系统疾病的治疗进展

年发文量:128 CiteScore:6.1 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:78.91%

杂志社联系方式:SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP

Therapeutic Advances In Neurological Disorders